The biology of glucagon and the consequences of hyperglucagonemia

Biomarkers in Medicine

Volumn 10, Issue 11, 2016, Pages 1141-1151

  Wewer Albrechtsen, Nicolai J ^a,b   Kuhre, Rune E ^a,b   Pedersen, Jens ^a,b   Knop, Filip K ^a,b,c   Holst, Jens J ^a,b  

^a UNIVERSITY OF COPENHAGEN   (Denmark)

^b Capital Region   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

diabetes; glucagon; hyperglucagonemia; proglucagon

Indexed keywords

GLUCAGON; GLUCAGON RECEPTOR; GLUCOSE; GLUCAGON LIKE PEPTIDE 1; OXYNTOMODULIN;

AMINO ACID METABOLISM; AMINOACIDEMIA; DIABETES MELLITUS; DISEASE ASSOCIATION; GLUCAGON RELEASE; GLUCONEOGENESIS; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLYCOGENOLYSIS; HORMONE ACTION; HORMONE BLOOD LEVEL; HUMAN; HYPERGLUCAGONEMIA; NONHUMAN; PANCREAS ISLET CELL HYPERPLASIA; REVIEW; BLOOD; CHEMISTRY; DEFICIENCY; GENETICS; GLUCAGONOMA; LIVER; METABOLISM; NEOPLASM; NONALCOHOLIC FATTY LIVER; PANCREAS; PATHOLOGY;

DIABETES MELLITUS; GLUCAGON; GLUCAGON-LIKE PEPTIDE 1; GLUCAGONOMA; HUMANS; LIVER; NEOPLASMS; NON-ALCOHOLIC FATTY LIVER DISEASE; OXYNTOMODULIN; PANCREAS; RECEPTORS, GLUCAGON;

EID: 84992432060     PISSN: 17520363     EISSN: 17520371     Source Type: Journal    
DOI: 10.2217/bmm-2016-0090     Document Type: Review

References (93)

1. Ramnanan CJ, Edgerton DS, Kraft G, Cherrington AD. Physiologic action of glucagon on liver glucose metabolism. Diabetes Obes. Metabol. 13, 118-125 (2011).
2. Raskin P, Unger RH. Hyperglucagonemia and its suppression. N. Engl. J. Med. 299(9), 433-436 (1978).
3. Perley MJ, Kipnis DM. Plasma insulin responses to oral and intravenous glucose: studies in normal and diabetic subjects. J. Clin. Invest. 46(12), 1954-1962 (1967).
4. Kimball CP, Murlin JR. Aqueous extracts of pancreas: III. Some precipitation reactions of insulin. J. Biol. Chem. 58(1), 337-346 (1923).
5. Cherrington A, Vranic M. Role of glucagon and insulin in control of glucose turnover. Metabolism 20(6), 625-628 (1971).
6. Berson SA, Yalow RS, Bauman A, Rothschild MA, Newerly K. Insulin-I131 metabolism in human subjects: demonstration of insulin binding globulin in the circulation of insulin treated subjects. J. Clin. Invest. 35(2), 170-190 (1956).
7. Unger RH, Cherrington AD. Glucagonocentric restructuring of diabetes: a pathophysiologic and therapeutic makeover. J. Clin. Invest. 122(1), 4-12 (2012).
8. Cherrington AD, Liljenquist JE, Shulman GI, Williams PE, Lacy WW. Importance of hypoglycemia-induced glucose production during isolated glucagon deficiency. Am. J. Physiol. 236(3), E263-E271 (1979).
9. Holst JJ, Madsen OG, Knop J, Schmidt A. The effect of intraportal and peripheral infusions of glucagon on insulin and glucose concentrations and glucose tolerance in normal man. Diabetologia 13(5), 487-490 (1977).
10. Brand CL, Jorgensen PN, Svendsen I, Hoist JJ. Evidence for a major role for glucagon in regulation of plasma glucose in conscious, nondiabetic, and alloxan-induced diabetic rabbits. Diabetes 45(8), 1076-1083 (1996).
11. Banting FG, Best CH, Collip JB, Campbell WR, Fletcher AA. Pancreatic extracts in the treatment of diabetes mellitus. Can. Med. Assoc. J. 12(3), 141-146 (1922).
12. Kazda CM, Garhyan P, Kelly RP et al. A randomized, double-blind, placebo-controlled Phase 2 study of the glucagon receptor antagonist LY2409021 in patients with Type 2 diabetes. Diabetes Care doi:10.2337/dc15-1643 (2015) (Epub ahead of print).
13. Bagger JI, Knop FK, Holst JJ, Vilsboll T. Glucagon antagonism as a potential therapeutic target in Type 2 diabetes. Diabetes Obes. Metab. 13(11), 965-971 (2011).
14. Solloway MJ, Madjidi A, Gu C et al. Glucagon couples hepatic amino acid catabolism to mTOR-dependent regulation of-cell mass. Cell Rep. 12(3), 495-510 (2015).
15. Olofsson CS, Salehi A, Gopel SO, Holm C, Rorsman P. Palmitate stimulation of glucagon secretion in mouse pancreatic alpha-cells results from activation of L-type calcium channels and elevation of cytoplasmic calcium. Diabetes 53(11), 2836-2843 (2004).
16. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, Holst JJ. Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig. Dis. Sci. 38(4), 665-673 (1993).
17. Baldissera FG, Holst JJ, Knuhtsen S, Hilsted L, Nielsen OV. Oxyntomodulin (glicentin-[33-69]): pharmacokinetics, binding to liver cell membranes, effects on isolated perfused pig pancreas, and secretion from isolated perfused lower small intestine of pigs. Regul. Pept. 21(1-2), 151-166 (1988).
18. Meier JJ, Gallwitz B, Siepmann N et al. Gastric inhibitory polypeptide (GIP) dose-dependently stimulates glucagon secretion in healthy human subjects at euglycemia. Diabetologia 46(6), 798-801 (2003).
19. Christensen M, Vedtofte L, Holst JJ, Vilsboll T, Knop FK. Glucose-dependent insulinotropic polypeptide: a bifunctional glucose-dependent regulator of glucagon and insulin secretion in humans. Diabetes 60(12), 3103-3109 (2011).
20. Holst JJ, Schwartz TW, Knuhtsen S, Jensen SL, Nielsen OV. Autonomic nervous control of the endocrine secretion from the isolated, perfused pig pancreas. J. Auton. Nerv. Syst. 17(1), 71-84 (1986).
21. Holst JJ, Christensen M, Lund A et al. Regulation of glucagon secretion by incretins. Diabetes Obes. Metab. 13(Suppl. 1), 89-94 (2011).
22. Hare KJ, Vilsboll T, Asmar M, Deacon CF, Knop FK, Holst JJ. The glucagonostatic and insulinotropic effects of glucagon-like peptide 1 contribute equally to its glucoselowering action. Diabetes 59(7), 1765-1770 (2010).
23. Wang Q, Liang X, Wang S. Intra-islet glucagon secretion and action in the regulation of glucose homeostasis. Front. Physiol. 3 485 (2012).
24. Gromada J, Franklin I, Wollheim CB.-cells of the endocrine pancreas: 35 years of research but the enigma remains. Endocr. Rev. 28(1), 84-116 (2007).
25. Kieffer TJ, Heller RS, Unson CG, Weir GC, Habener JF. Distribution of glucagon receptors on hormone-specific endocrine cells of rat pancreatic islets. Endocrinology 137(11), 5119-5125 (1996).
26. Cooperberg BA, Cryer PE. Insulin reciprocally regulates glucagon secretion in humans. Diabetes 59(11), 2936-2940 (2010).
27. Kawamori D, Kurpad AJ, Hu J et al. Insulin signaling in alpha cells modulates glucagon secretion in vivo. Cell Metab. 9(4), 350-361 (2009).
28. Moens K, Heimberg H, Flamez D et al. Expression and functional activity of glucagon, glucagon-like peptide I, and glucose-dependent insulinotropic peptide receptors in rat pancreatic islet cells. Diabetes 45(2), 257-261 (1996).
29. Moens K, Flamez D, Schravendijk CV, Ling Z, Pipeleers D, Schuit F. Dual glucagon recognition by pancreatic-cells via glucagon and glucagon-like peptide 1 receptors. Diabetes 47(1), 66-72 (1998).
30. Wewer Albrechtsen NJ, Hornburg D, Albrechtsen R et al. Oxyntomodulin identified as a marker of Type 2 diabetes and gastric bypass surgery by mass-spectrometry based profiling of human plasma. EBioMedicine doi:10.1016/j. ebiom.2016.03.034 (2016) (Epub ahead of print).
31. Campbell JE, Drucker DJ. Islet cells and glucagon-critical regulators of energy homeostasis. Nat. Rev. Endocrinol. 11(6), 329-338 (2015).
32. Habegger KM, Stemmer K, Cheng C et al. Fibroblast growth factor 21 mediates specific glucagon actions. Diabetes 62(5), 1453-1463 (2013).
33. Von Holstein-Rathlou S, Bondurant LD, Peltekian L et al. FGF21 mediates endocrine control of simple sugar intake and sweet taste preference by the liver. Cell Metab. 23(2), 335-343 (2016).
34. Tan BK, Hallschmid M, Adya R, Kern W, Lehnert H, Randeva HS. Fibroblast growth factor 21 (FGF21) in human cerebrospinal fluid: relationship with plasma FGF21 and body adiposity. Diabetes 60(11), 2758-2762 (2011).
35. Mery P-F, Brechler V, Pavoine C, Pecker F, Fischmeister R. Glucagon stimulates the cardiac Ca2+ current by activation of adenylyl cyclase and inhibition of phosphodiesterase. Nature 345(6271), 158-161 (1990).
36. Mochiki E, Suzuki H, Takenoshita S et al. Mechanism of inhibitory effect of glucagon on gastrointestinal motility and cause of side effects of glucagon. J. Gastroenterol. 33(6), 835-841 (1998).
37. Brereton MF, Vergari E, Zhang Q, Clark A. Alpha-, deltaand PP-cells: are they the architectural cornerstones of islet structure and co-ordination J. Histochem. Cytochem. 63(8), 575-591 (2015).
38. Sandoval DA, D'alessio DA. Physiology of proglucagon peptides: role of glucagon and GLP-1 in health and disease. Physiol. Rev. 95(2), 513-548 (2015).
39. Bak MJ, Albrechtsen NW, Pedersen J et al. Specificity and sensitivity of commercially available assays for glucagon and oxyntomodulin measurement in humans. Eur. J. Endocrinol. 170(4), 529-538 (2014).
40. Chesher D. Evaluating assay precision. Clin. Biochem. Rev. 29(Suppl. 1), S23-S26 (2008).
41. Holst, Pedersen JH, Baldissera F, Stadil F. Circulating glucagon after total pancreatectomy in man. Diabetologia 25(5), 396-399 (1983).
42. Muller WA, Girardier L, Seydoux J, Berger M, Renold AE, Vranic M. Extrapancreatic glucagon and glucagonlike immunoreactivity in depancreatized dogs: a quantitative assessment of secretion rates and anatomical delineation of sources. J. Clin. Invest. 62(1), 124-132 (1978).
43. Lund A, Bagger JI, Wewer Albrechtsen NJ et al. Evidence of extrapancreatic glucagon secretion in man. Diabetes 65(3), 585-597 (2015).
44. Holst JJ. Extrapancreatic glucagons. Digestion 17(2), 168-190 (1978).
45. Wewer Albrechtsen N, Hartmann B, Veedfald S et al. Hyperglucagonaemia analysed by glucagon sandwich ELISA: nonspecific interference or truly elevated levels Diabetologia 57(9), 1919-1926 (2014).
46. Bak MJ, Albrechtsen NW, Hartmann B et al. Effect of aprotinin (Trasylol™) on degradation of exogenous and endogenous glucagon in human, mouse and rat plasma. J. Endocrinol. Diabetes 1(1), 5 (2014).
47. Wewer Albrechtsen NJ, Veedfald S, Plamboeck A et al. Inability of some commercial assays to measure suppression of glucagon secretion. J. Diabetes Res. 2016, 5 (2016).
48. Wewer Albrechtsen NJ, Bak MJ, Hartmann B et al. Stability of glucagon-like peptide-1 and glucagon in human plasma. Endocr. Connect. 4(1), 50-57 (2015).
49. Reaven GM, Chen Y-DI, Golay A, Swislocki ALM, Jaspan JB. Documentation of hyperglucagonemia throughout the day in nonobese and obese patients with noninsulindependent diabetes mellitus. J. Clin. Endocrinol. Metabol. 64(1), 106-110 (1987).
50. Unger RH, Aguilar-Parada E, Müller WA, Eisentraut AM. Studies of pancreatic alpha cell function in normal and diabetic subjects. J. Clin. Invest. 49(4), 837-848 (1970).
51. Knop FK, Aaboe K, Vilsboll T et al. Impaired incretin effect and fasting hyperglucagonaemia characterizing Type 2 diabetic subjects are early signs of dysmetabolism in obesity. Diabetes Obes. Metab. 14(6), 500-510 (2012).
52. Mitrakou A, Kelley D, Mokan M et al. Role of reduced suppression of glucose production and diminished early insulin release in impaired glucose tolerance. N. Engl. J. Med. 326(1), 22-29 (1992).
53. Moon JS, Won KC. Pancreatic-cell dysfunction in Type 2 diabetes: old kids on the block. Diabetes Metab. J. 39(1), 1-9 (2015).
54. Knop FK, Vilsboll T, Madsbad S, Holst JJ, Krarup T. Inappropriate suppression of glucagon during OGTT but not during isoglycaemic i.v. glucose infusion contributes to the reduced incretin effect in Type 2 diabetes mellitus. Diabetologia 50(4), 797-805 (2007).
55. Hare KJ, Vilsboll T, Holst JJ, Knop FK. Inappropriate glucagon response after oral compared with isoglycemic intravenous glucose administration in patients with Type 1 diabetes. Am. J. Physiol. Endocrinol. Metab. 298(4), E832-E837 (2010).
56. Wang M-Y, Yan H, Shi Z et al. Glucagon receptor antibody completely suppresses Type 1 diabetes phenotype without insulin by disrupting a novel diabetogenic pathway. Proc. Natl Acad. Sci. USA 112(8), 2503-2508 (2015).
57. Lee Y, Wang M-Y, Du XQ, Charron MJ, Unger RH. Glucagon receptor knockout prevents insulin-deficient Type 1 diabetes in mice. Diabetes 60(2), 391-397 (2011).
58. Brand CL, Rolin B, Jorgensen PN, Svendsen I, Kristensen JS, Holst JJ. Immunoneutralization of endogenous glucagon with monoclonal glucagon antibody normalizes hyperglycaemia in moderately streptozotocin-diabetic rats. Diabetologia 37(10), 985-993 (1994).
59. Okamoto H, Kim J, Aglione J et al. Glucagon receptor blockade with a human antibody normalizes blood glucose in diabetic mice and monkeys. Endocrinology 156(8), 2781-2794 (2015).
60. Steenberg VR, Jensen SM, Pedersen J et al. Acute disruption of glucagon secretion or action does not improve glucose tolerance in an insulin-deficient mouse model of diabetes. Diabetologia 59(2), 363-370 (2015).
61. Gelling RW, Du XQ, Dichmann DS et al. Lower blood glucose, hyperglucagonemia, and pancreatic cell hyperplasia in glucagon receptor knockout mice. Proc. Natl Acad. Sci. USA 100(3), 1438-1443 (2003).
62. Longuet C, Robledo AM, Dean ED et al. Liver-specific disruption of the murine glucagon receptor produces-cell hyperplasia: evidence for a circulating-cell growth factor. Diabetes 62(4), 1196-1205 (2012).
63. Jun LS, Millican RL, Hawkins ED et al. Absence of glucagon and insulin action reveals a role for the GLP-1 receptor in endogenous glucose production. Diabetes 64(3), 819-827 (2015).
64. Ferrannini E, Muscelli E, Frascerra S et al. Metabolic response to sodium-glucose cotransporter 2 inhibition in Type 2 diabetic patients. J. Clin. Invest. 124(2), 499-508
65. Ahrén B, Larsson H. Impaired glucose tolerance (IGT) is associated with reduced insulin-induced suppression of glucagon concentrations. Diabetologia 44(11), 1998-2003.
66. Faerch K, Vaag A, Holst JJ, Hansen T, Jorgensen T, Borch-Johnsen K. Natural history of insulin sensitivity and insulin secretion in the progression from normal glucose tolerance to impaired fasting glycemia and impaired glucose tolerance: the Inter99 study. Diabetes Care 32(3), 439-444 (2009).
67. Jamison RA, Stark R, Dong J et al. Hyperglucagonemia precedes a decline in insulin secretion and causes hyperglycemia in chronically glucose-infused rats. Am. J. Physiol. 301(6), E1174-E1183 (2011).
68. Song W-J, Mondal P, Wolfe A et al. Glucagon regulates hepatic kisspeptin to impair insulin secretion. Cell Metab. 19(4), 667-681 (2014).
69. Wewer Albrechtsen NJ, Challis B, Damjanov I, Holst JJ. Do glucagonomas always produce glucagon Bosn. J. Basic Med. Sci. 16(1), 1-7 (2016).
70. Holst JJ. Molecular heterogeneity of glucagon in normal subjects and in patients with glucagon-producing tumours. Diabetologia 24(5), 359-365 (1983).
71. Challis BG, Albrechtsen NJW, Bansiya V et al. Heterogeneity of glucagonomas due to differential processing of proglucagon-derived peptides. Endocrinol. Diabetes Metabol. Case Rep. 2015, 150105 (2015).
72. Alexander EK, Robinson M, Staniec M, Dluhy RG. Peripheral amino acid and fatty acid infusion for the treatment of necrolytic migratory erythema in the glucagonoma syndrome. Clin. Endocrinol. (Oxf.) 57(6), 827-831 (2002).
73. Guimarães M, Rodrigues P, Pereira SS et al. GLP1 and glucagon co-secreting pancreatic neuroendocrine tumor presenting as hypoglycemia after gastric bypass. Endocrinol. Diabetes Metabol. Case Rep. 2015, 150049 (2015).
74. Toft-Nielsen M, Madsbad S, Holst JJ. Exaggerated secretion of glucagon-like peptide-1 (GLP-1) could cause reactive hypoglycaemia. Diabetologia 41(10), 1180-1186 (1998).
75. Taborsky GJ Jr. The physiology of glucagon. J. Diabetes Sci. Technol. 4(6), 1338-1344 (2010).
76. Blauw H, Wendl I, Devries JH, Heise T, Jax T. Pharmacokinetics and pharmacodynamics of various glucagon dosages at different blood glucose levels. Diabetes Obes. Metab. 18(1), 34-39 (2016).
77. Rohrer S, Menge BA, Grüber L et al. Impaired crosstalk between pulsatile insulin and glucagon secretion in prediabetic individuals. J. Clin. Endocrinol. Metabol. 97(5), E791-E795 (2012).
78. Dobbins RL, Davis SN, Neal DW, Cobelli C, Cherrington AD. Pulsatility does not alter the response to a physiological increment in glucagon in the conscious dog. Am. J. Physiol. 266(3 Pt 1), E467-E478 (1994).
79. Rivera N, Ramnanan CJ, An Z et al. Insulin-induced hypoglycemia increases hepatic sensitivity to glucagon in dogs. J. Clin. Invest. 120(12), 4425-4435 (2010).
80. Livingston JN, Einarsson K, Backman L, Ewerth S, Arner P. Glucagon receptor of human liver. Studies of its molecular weight and binding properties, and its ability to activate hepatic adenylyl cyclase of non-obese and obese subjects. J. Clin. Invest. 75(2), 397-403 (1985).
81. Raddatz D, Roßbach C, Buchwald A, Scholz KH, Ramadori G, Nolte W. Fasting hyperglucagonemia in patients with transjugular intrahepatic portosystemic shunts (TIPS). Exp. Clin. Endocrinol. Diabetes 113(5), 268-274 (2005).
82. McDonald TJ, Dupre J, Caussignac Y, Radziuk J, Van Vliet S. Hyperglucagonemia in liver cirrhosis with portal-systemic venous anastomoses: responses of plasma glucagon and gastric inhibitory polypeptide to oral or intravenous glucose in cirrhotics with normal or elevated fasting plasma glucose levels. Metabolism 28(4), 300-307 (1979).
83. Jelinek LJ, Lok S, Rosenberg GB et al. Expression cloning and signaling properties of the rat glucagon receptor. Science 259(5101), 1614-1616 (1993).
84. Dunphy JL, Taylor RG, Fuller PJ. Tissue distribution of rat glucagon receptor and GLP-1 receptor gene expression. Mol. Cell. Endocrinol. 141(1-2), 179-186 (1998).
85. Parker JC, Andrews KM, Allen MR, Stock JL, McNeish JD. Glycemic control in mice with targeted disruption of the glucagon receptor gene. Biochem. Biophys. Res. Commun. 290(2), 839-843 (2002).
86. Sipos B, Sperveslage J, Anlauf M et al. Glucagon cell hyperplasia and neoplasia with and without glucagon receptor mutations. J. Clin. Endocrinol. Metabol. 100(5), E783-E788 (2015).
87. Hayashi Y, Yamamoto M, Mizoguchi H et al. Mice deficient for glucagon gene-derived peptides display normoglycemia and hyperplasia of islet {alpha}-cells but not of intestinal L-cells. Mol. Endocrinol. 23(12), 1990-1999 (2009).
88. Webb GC, Akbar MS, Zhao C, Swift HH, Steiner DF. Glucagon replacement via micro-osmotic pump corrects hypoglycemia and-cell hyperplasia in prohormone convertase 2 knockout mice. Diabetes 51(2), 398-405 (2002).
89. Almdal TP, Holst JJ, Heindorff H, Vilstrup H. Glucagon immunoneutralization in diabetic rats normalizes urea synthesis and decreases nitrogen wasting. Diabetes 41(1), 12-16 (1992).
90. Heibel SK, Lopez GY, Panglao M et al. Transcriptional regulation of N-acetylglutamate synthase. PLoS ONE 7(2), e29527 (2012).
91. Takiguchi M, Mori M. Transcriptional regulation of genes for ornithine cycle enzymes. Biochem. J. 312(Pt 3), 649-659 (1995).
92. Watanabe C, Seino Y, Miyahira H et al. Remodeling of hepatic metabolism and hyperaminoacidemia in mice deficient in proglucagon-derived peptides. Diabetes 61(1), 74-84 (2012).
93. Junker AE, Gluud L, Holst JJ, Knop FK, Vilsboll T. Diabetic and nondiabetic patients with nonalcoholic fatty liver disease have an impaired incretin effect and fasting hyperglucagonaemia. J. Intern. Med. 279(5), 485-493 (2016).